|
|
Post by liane on Jun 28, 2014 5:18:41 GMT -5
|
|
|
|
Post by savzak on Jun 28, 2014 6:43:10 GMT -5
It's been mentioned many times before that all "viewpoints", long, short, or whatever are welcome here. But you gotta at least have a leg to stand on. Approval yesterday knocked out 95% of the short thesis. The ball is clearly in Al Mann's court now and all the pieces are coming together. Now that the FDA constraint has been removed, Al can demonstrate the successful entrepreneur skills that he has. Next step - partnership - which I think will come swiftly. It's important to build on the momentum that will be generated by news of this novel diabetes treatment. It's important to get this drug in front of the doctors who will prescribe it. But once it's in the hands of patients, there will be no stopping it. The majority of study participants successfully and conveniently transitioned to this new paradigm. Word will spread, and patients will demand it. Perfect. I wouldn't change a word of this post. I've said for months, if not years that approval was THE OBSTACLE to be cleared. Though the FDA will unfortunately never be out of the MannKind picture altogether, it is no longer standing guard between Arrezza and the market. The door to the market has been unlocked and opened wide. Now management can get on with BUSINESS. |
|
|
|
Post by 4allthemarbles on Jun 28, 2014 21:13:21 GMT -5
Liane- that picture is perfect.
|
|
